Changes in therapy and survival of metastatic renal cell carcinoma in Estonia

BACKGROUND: Before the era of targeted therapies, cytokines were the main therapy for metastatic renal cell carcinoma (mRCC). Our aim was to analyze the changes in treatments and overall survival (OS) of all mRCC patients in Estonia in relation to the introduction of new medications. METHODS: All pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Jürgens, Hannes, Ojamaa, Kristiina, Pokker, Helis, Innos, Kaire, Padrik, Peeter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068934/
https://www.ncbi.nlm.nih.gov/pubmed/32164576
http://dx.doi.org/10.1186/s12885-020-6685-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068934/
https://www.ncbi.nlm.nih.gov/pubmed/32164576
http://dx.doi.org/10.1186/s12885-020-6685-y

Ejemplares similares